Stanford Children’s Inflammatory Bowel Disease Program

09/18/2020

Connect with the Pediatric IBD Community during the free, virtual online conference hosted by ImproveCareNow. A few members of the Stanford team will be presenting on our virtual engagement events on September 25th. We hope to see you there!

On September 24 & 25 we will be hosting our 𝗙𝗮𝗹𝗹 𝟮𝟬𝟮𝟬 𝗟𝗶𝘃𝗲 𝗢𝗻𝗹𝗶𝗻𝗲 𝗖𝗼𝗺𝗺𝘂𝗻𝗶𝘁𝘆 𝗖𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲. We plan to 'all teach and all learn' about topics including diversity & equity, patient & family engagement, the effects of COVID-19 on health and care, and our path forward with new ICN leadership. The event is open to all so we hope to 'see' you there 💚💙

Download the agenda and make a plan to join us: https://www.improvecarenow.org/fall_2020_community_conference

03/17/2018

Check it out, friends! Our IBD Center produced a Cooking Night Video at Sur La Table in Palo Alto!

Patients, Parents, & Stanford Providers cooking together...

This is "Final short video" by ZWEEN WORKS on Vimeo, the home for high quality videos and the people who love them.

01/29/2018

Showcasing our latest study now published.

We want to deliver the right medication dose to the right patients.

One size-fits-all approach to drug dosing is not appropriate (especially in young patients) since each patient is different.

Check out our free, open-access manuscript here:

BackgroundInadequate infliximab (IFX) drug exposure remains a clinical challenge and leads to high loss of response rates and therapy failure in inflammatory bowel disease (IBD). We aimed to determine the feasibility and pilot effectiveness of a novel, web-based, mobile IFX dosing calculator (mIDC)....

01/26/2018

Members of our IBD Center presented and co-lead several components of last week's inaugural Crohns & Colitis Congress: http://www.crohnscolitiscongress.org/CCC1/Public/Content.aspx?ID=31&sortMenu=102001

Many exciting scientific frontiers presented, and here's a snippet of what we saw/heard on diet & IBD:
http://www.crohnscolitiscongress.org/CCC1/Public/Content.aspx?ID=31&sortMenu=102001

Join the Crohn’s & Colitis Foundation (formerly known as the CCFA) and American Gastroenterological Association (AGA) for the inaugural Crohn’s & Colitis Congress™. Expand your knowledge, network with IBD leaders across multiple disciplines, and get inspired to improve patient care.

01/06/2018

Happy New Year everyone!

Two really interesting articles to share:

1) A western diet high in salt may cause imbalances in gut bacteria, decreasing beneficial Lactobacillus species. Hypertension and autoimmunity (via T-helper 17 cells) could be *triggered* via this proposed pathway.

https://www.nature.com/articles/nature24628

2) A diet high in carbohydrates (collectively called FODMAPs) could induce intestinal inflammation by activating gram-negative bacteria to produce lipopolysaccharides (LPS) - endotoxins that are found on certain pro-inflammatory bacteria walls that may illicit our human immunity.

https://www.jci.org/articles/view/92390

These two articles REITERATE the importance of what we eat, especially if have or disease.

High salt intake changed the gut microbiome and increased TH17 cell numbers in mice, and reduced intestinal survival of Lactobacillus species, increased the number of TH17 cells and increased blood pressure in humans.

12/22/2017

More research on how what we eat can affect IBD --

Diets with high levels of fatty acids such as myristic acid (found in palm oil, coconut oil, and dairy fats) increased risk of flare in patients with ulcerative colitis (UC), researchers report in …

11/22/2017

Read our latest research from our Center. To date, it is the most comprehensive analysis of real-world costs and use of IBD medications for outpatient care.

(http://onlinelibrary.wiley.com/doi/10.1111/apt.14430/full)

Why does this study matter? Knowing, discussing, and questioning costs of care in IBD is important. It is particularly important as costs of chronic conditions outpace our budgets -- at the national-, health care system-, and individual-levels. It matters because out-of-pocket costs (to families) matter. It matters because potentially helpful drugs are increasingly difficult to access.

Real‐world data quantifying the costs of increasing use of biologics in inflammatory bowel disease (IBD) are unknown.To determine the outpatient IBD drug utilization trends, relative market share, and...

11/07/2017

Congrats to our Stanford Children's Health - Lucile Packard Children's Hospital Stanford IBD Center's Parent Partners, Mary McGowan, Candace Kelley & Mary Jo McCarthy and team, for receiving one of the inaugural Patient & Parent Innovation Fund Award!!!

http://www.improvecarenow.org/two_projects_funded_through_inaugural_improvecarenow_patient_and_parent_innovation_fund

10/10/2017

Come join us on October 28 at this year's Crohn's & Colitis Foundation Bay Area Patient Education Conference. Two of our IBD Center docs will be presenting!

http://online.ccfa.org/site/Calendar?view=Detail&id=143851

When: Saturday, October 28, 2017, 10:00 AM to 3:00 PM
Where: UC Berkeley Clark Kerr Conference Center
2601 Warring Street
Berkeley, CA 94720

Crohn's & Colitis Foundation

07/29/2017

The Pain cycle - applicable in IBD

07/29/2017

Snapshots from:
http://www.nature.com/nrgastro/journal/vaop/ncurrent/full/nrgastro.2017.88.html

1) Inflammation and microbiota (e.g., bacteria & fungus) are intricately connected. But it's difficult to tease out cause or just association.

2) Regardless, it's important to approach IBD therapies from different angles (i.e., adherence to evidence-based therapies modulating inflammation & lifestyle modifications to improve gut microbiota health through diet, stress management, and exercise, etc)

07/25/2017

Here is our paper in Open Access - we wanted our scientific paper to be available to patients, families, to all...

Why we monitor calprotectin levels...

http://journals.lww.com/ibdjournal/Pages/ArticleViewer.aspx?year=2017&issue=06000&article=00007&type=Fulltext

Background: In asymptomatic patients with inflammatory bowel disease (IBD), “monitoring” involves repeated testing aimed at early recognition of disease exacerbation. We aimed to determine the usefulness of repeated f***l calprotectin (FC) measurements to predict IBD relapses by a systematic lite...